- Report
- July 2026
- 160 Pages
Global
From €4460EUR$4,750USD£3,721GBP
- Report
- July 2026
- 160 Pages
Global
From €4460EUR$4,750USD£3,721GBP
- Report
- August 2026
- 160 Pages
Global
From €3117EUR$3,320USD£2,601GBP
€3896EUR$4,150USD£3,251GBP
- Report
- August 2026
- 100 Pages
Latin America
From €4460EUR$4,750USD£3,721GBP
- Report
- July 2026
- 80 Pages
Europe
From €4460EUR$4,750USD£3,721GBP
- Report
- July 2026
- 150 Pages
North America
From €4460EUR$4,750USD£3,721GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3380EUR$3,600USD£2,820GBP
- Report
- August 2026
- 200 Pages
Saudi Arabia
From €2338EUR$2,490USD£1,950GBP
- Report
- March 2025
- 200 Pages
Global
From €2338EUR$2,490USD£1,950GBP
- Report
- August 2025
- 197 Pages
Global
From €3328EUR$3,545USD£2,777GBP
€3698EUR$3,939USD£3,085GBP
- Report
- January 2024
- 200 Pages
Global
From €3896EUR$4,150USD£3,251GBP
- Report
- February 2024
- 70 Pages
Iran
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
India
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
United States
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Spain
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Iran
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
Australia
From €4460EUR$4,750USD£3,721GBP
- Report
- February 2024
- 70 Pages
North America
From €4460EUR$4,750USD£3,721GBP

Sulfonylureas are a class of drugs used to treat type 2 diabetes. They work by stimulating the pancreas to produce more insulin, which helps the body to better process glucose. They are usually taken orally, and are often used in combination with other diabetes medications. Sulfonylureas are generally well-tolerated, but can cause side effects such as hypoglycemia, weight gain, and gastrointestinal upset.
The sulfonylureas market is a subset of the larger diabetes drugs market. It is a competitive market, with a range of products available from different manufacturers. The market is expected to grow in the coming years, driven by increasing prevalence of diabetes and the development of new drugs.
Some of the major companies in the sulfonylureas market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more